Onco3R Therapeutics Unveils Promising Preclinical Data
Onco3R Therapeutics, a clinical-stage biotech firm focused on immunology and oncology, has recently announced its innovative strides in precision oncology. The company is set to present compelling preclinical data regarding its lead small molecule programs, including potential best-in-class FGFR3 selective inhibitors, SMARCA2 inhibitors, and P53 Y220C reactivators.
Presentation at Major Cancer Symposium
At the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Onco3R will showcase three detailed posters that highlight their leading research. This significant scientific event is a hub for cutting-edge research, and Onco3R's presence emphasizes their commitment to advancing oncology treatments.
Highlighting Key Programs
François Gonzalvez, PhD, Chief Scientific Officer and co-Founder of Onco3R Therapeutics, noted the strategic importance of their programs aimed at overcoming limitations posed by existing therapies. According to him, "First-generation precision medicines often fall short in clinical settings due to factors such as low target coverage and the emergence of resistance. Our aim is to develop best-in-class treatments that address these constraints effectively."
Promising Preclinical Results
The preclinical studies reveal the effectiveness of their FGFR3 and SMARCA2 candidates. The compounds—named G-012 and G-141—demonstrated optimal potency and selectivity, minimizing dose-limiting toxicities while ensuring maximum efficacy against targeted cancer pathways. These compounds have shown remarkable anti-tumor activities in in vivo models. In particular, G-012 exhibited significant anti-proliferative effects in cancer cells driven by FGFR3 and marked tumor regression.
Details of Presentations
Onco3R's poster presentations will detail their findings, which substantiate the advancement of both G-012 and G-141 toward clinical development. Here’s what attendees can expect:
FGFR3 Small Molecule Inhibitor
The presentation titled “Discovery of Best-in-Class FGFR3 small molecule inhibitors with high isoform selectivity and activity against gatekeeper mutations” will be led by Sandrine Vendeville, PhD. This poster outlines how G-012 shows best-in-class potency through favorable drug-like properties, ensuring potent selectivity against other FGFR isoforms.
SMARCA2 Small Molecule Inhibitor
The second presentation will delve into SMARCA2, led by Lijs Beke, PhD. Onco3R’s novel SMARCA2 inhibitor, G-141, has demonstrated significant efficacy, particularly in SMARCA4-deficient cancers, unveiling its potential to improve patient outcomes while avoiding toxicity associated with current treatments.
P53 Reactivation for Enhanced Oncology Treatment
Furthermore, Onco3R plans to present their work on a unique small molecule that reactivates P53, providing insights into overcoming traditional potency barriers. The presentation will highlight the breakthrough findings that these compounds exhibit profound anti-proliferative activity in cancer models featuring the P53 Y220C mutation.
About Onco3R Therapeutics
Onco3R Therapeutics is committed to revolutionizing treatment paradigms for patients struggling with cancer and autoimmune diseases. With a robust team bringing substantial R&D expertise, the company focuses on addressing unmet medical needs through best-in-class therapeutic design. They aim to integrate advanced drug discovery technologies with deep scientific understanding to guide their mission.
Their current project portfolio is anchored in strategic studies that enhance their pipeline, including their promising SIK3 inhibitor, O3R-5671, aimed at treating autoimmune disorders. By harnessing advanced methodologies and valuable learnings from prior clinical endeavors, Onco3R seeks to expeditiously deliver innovative therapies with demonstrable benefits for patients.
Frequently Asked Questions
What is Onco3R Therapeutics known for?
Onco3R Therapeutics is known for developing innovative therapies focusing on precision oncology, particularly in small molecule inhibitors targeting specific cancer pathways.
What are the major compounds being presented by Onco3R?
The major compounds include their FGFR3 selective inhibitor G-012, SMARCA2 selective inhibitor G-141, and the P53 Y220C reactivator.
Where is Onco3R based?
Onco3R Therapeutics is based in Belgium, within a notable biotech cluster.
When are IND-enabling studies expected to commence?
IND-enabling studies for their candidates are anticipated to start in mid-2026.
How does Onco3R approach drug discovery?
Onco3R adopts a patient-centric approach to drug discovery, combining translational science with AI-driven methodologies for better efficacy and safety in treatments.
